AbbVie (NASDAQ:ABBV) has been given an “A-” credit rating by analysts at Morningstar. The firm’s “A-” rating suggests that the company is a low default risk. They also gave their stock a two star rating.
A number of other research analysts have also weighed in on ABBV. BMO Capital Markets reiterated an “outperform” rating and set a $68.00 target price on shares of AbbVie in a research report on Monday, April 27th. Credit Suisse restated an “outperform” rating and issued a $69.00 price objective on shares of AbbVie in a research report on Saturday, May 9th. JPMorgan Chase & Co. started coverage on AbbVie in a research note on Wednesday, May 27th. They issued an “overweight” rating and a $75.00 target price for the company. Cowen and Company set a $72.00 price target on AbbVie and gave the stock a “buy” rating in a research note on Wednesday, May 27th. Finally, Morgan Stanley assumed coverage on AbbVie in a research note on Thursday, May 28th. They issued an “equal weight” rating and a $72.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $73.94.
Shares of AbbVie (NASDAQ:ABBV) opened at 63.45 on Tuesday. The firm has a market capitalization of $105.03 billion and a PE ratio of 49.34. The company has a 50-day moving average price of $69.10 and a 200 day moving average price of $64.54. AbbVie has a 52-week low of $52.06 and a 52-week high of $71.60.
AbbVie (NASDAQ:ABBV) last posted its quarterly earnings data on Friday, July 24th. The company reported $1.08 EPS for the quarter, topping the analysts’ consensus estimate of $1.06 by $0.02. During the same quarter in the previous year, the firm posted $0.82 earnings per share. The business earned $5.48 billion during the quarter, compared to the consensus estimate of $5.60 billion. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. Analysts expect that AbbVie will post $4.26 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a $0.51 dividend. The ex-dividend date was Monday, July 13th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 3.22%.
AbbVie Inc. (NASDAQ:ABBV) is a global, research-based biopharmaceutical firm. The Company promotes and develops treatments that address a range of ailments. The Business ‘s products are focused on treating conditions, for example persistent autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid ailment; Parkinson’s disease; complications related to chronic kidney disease and cystic fibrosis, and other health circumstances, such as low testosterone. AbbVie also has a pipeline of new medications, including more than indications or 30 compounds in Phase II or Phase III development across a variety of medical specialties, like immunology, virology/liver disease, oncology, renal disease, neurological diseases as well as women’s well-being. The Company’s product portfolio comprises HCV merchandises HUMIRA, Additional Virology merchandises, Metabolics/Hormones merchandises, Endocrinology products and other products.
To view more credit ratings from Morningstar, visit www.jdoqocy.comclick-7674909-10651170.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.